PEG-MGF
Summary
PEG-MGF is the PEGylated form of mechano growth factor (MGF), the 24-amino acid C-terminal E-peptide of the IGF-1Ec splice variant, modified with polyethylene glycol to extend its very short half-life. In human cell studies the MGF E-peptide activates muscle satellite cells and increases their fusion potential through a pathway independent of the IGF-1 receptor. All evidence is in vitro or animal; no human trials exist, and mechano growth factors are banned in sport by WADA.
Also known as: Pegylated Mechano Growth Factor, PEG IGF-1Ec, Pegylated MGF E-Peptide
Key Findings at a Glance
- • The MGF E-peptide acts through a receptor distinct from the IGF-1 receptor: neutralizing IGF-1R antibodies block mature IGF-1 but not the E-peptide, which activates ERK1/2 without Akt in cardiomyocyte models.
- • In human muscle cell cultures, the 24-aa MGF E-peptide extended proliferative lifespan and delayed senescence in satellite cells from young but not elderly donors, while depleting the reserve cell pool in all age groups.
- • Systemic or intramuscular delivery of synthetic MGF E-peptide significantly improved engraftment of transplanted human muscle precursor cells in mice, linking the peptide to cell therapy research.
- • Sustained MGF overexpression in injured mouse muscle delayed resolution of pro-inflammatory macrophages without improving regeneration, a cautionary signal for chronic exposure.
PEG-MGF Overview & Molecular Profile
PEG-MGF is a PEGylated analog of mechano growth factor (MGF), a splice variant of insulin-like growth factor 1 also called IGF-1Ec. In humans, a 49-base-pair insert during IGF-1 gene splicing shifts the reading frame and produces a distinct C-terminal E domain; MGF expression rises in muscle after mechanical loading and injury and declines with age and in dystrophic muscle. The synthetic research peptide corresponds to the terminal 24 amino acids of this E domain (the MGF E-peptide), and PEGylation - covalent attachment of polyethylene glycol - is used to slow the rapid degradation that limits the unmodified peptide. The evidence base is preclinical: Yang and Goldspink showed in 2002 that the MGF E domain stimulates myoblast proliferation while delaying terminal differentiation, unlike mature IGF-1, and Kandalla et al. (2011) showed the 24-aa E-peptide activates human muscle progenitor cells with strongly age-dependent effects. A 2018 mouse study added a cautionary note, finding that sustained MGF overexpression delayed macrophage resolution after injury. No human trial has been published, no formal pharmacokinetic study of PEG-MGF exists, and mechano growth factors are named on the WADA Prohibited List.
Mechanism of Action: Hormonal Signaling & Receptor Binding
The MGF E-peptide acts through a receptor distinct from the IGF-1 receptor: blocking IGF-1R with neutralizing antibodies abolishes the effects of mature IGF-1 but not those of the synthetic MGF E-peptide, in both myoblast and cardiomyocyte models. In H9C2 cardiomyocytes the peptide activated ERK1/2 phosphorylation without activating Akt, consistent with a mitogen-activated signaling profile separate from canonical IGF-1R pathways. Functionally, the E-peptide expands the muscle progenitor pool: it increases satellite cell proliferation, promotes migration of myogenic precursor cells, and delays their terminal differentiation, thereby increasing the number of cells available to fuse into repairing fibers. The identity of the E-peptide receptor remains uncharacterized in the published literature.
Research-Observed Effects
Muscle Satellite Cell Activation
Moderate ResearchThe core documented effect of the MGF E-peptide is activation of muscle satellite (stem) cells. In the Kandalla 2011 study of primary human muscle cell cultures, the synthetic 24-aa MGF E-peptide increased the proliferative lifespan and delayed senescence of satellite cells isolated from neonatal and young adult donors, and increased the fusion potential of activated cells across age groups. Earlier work by Yang and Goldspink (2002) established that the MGF E domain increases myoblast proliferation while holding back terminal differentiation, the opposite balance to mature IGF-1, which drives differentiation. Evidence comes from multiple independent laboratories but remains entirely in vitro and preclinical.
Myogenic Precursor Migration and Engraftment
Preliminary ResearchA 2007 study by Mills and colleagues showed that a synthetic 24-aa MGF E-peptide enhanced proliferation of human myogenic precursor cells in vitro and that intramuscular or systemic delivery of the peptide significantly improved engraftment of transplanted human muscle precursor cells in mice. The effect was attributed to enhanced proliferation combined with delayed differentiation of the transplanted cells, and it occurred independently of IGF-1 receptor binding. These findings position the E-peptide as a research tool for cell-based muscle therapies, though no clinical translation has followed.
Age-Dependent Progenitor Response
Preliminary ResearchThe Kandalla 2011 study found a marked donor-age effect: the MGF E-peptide extended proliferative lifespan and delayed senescence in satellite cells from neonatal and young adult muscle but not in cells from a 73-year-old donor. Hypertrophy with a significant reduction in the reserve cell population was observed in treated cultures of all ages, indicating the peptide can consume the quiescent progenitor pool it expands. This age dependence is a central caveat for translating MGF biology to sarcopenia research.
IGF-1R-Independent ERK1/2 Signaling
Moderate ResearchMechanistic studies converge on an IGF-1 receptor-independent mode of action. Neutralizing IGF-1R antibodies failed to block MGF E-peptide effects on myoblast proliferation (Yang 2002), human precursor cell proliferation (Mills 2007), and H9C2 cardiomyocyte responses (Stavropoulou 2009), while fully blocking mature IGF-1 in the same experiments. In the cardiomyocyte work the peptide activated ERK1/2 but not Akt phosphorylation. The responsible receptor has not been identified, which limits pharmacological characterization.
Muscle Injury Inflammation Effects
Preliminary ResearchA 2018 Frontiers in Physiology study examined MGF in cardiotoxin-injured mouse muscle and found that infiltrating macrophages are a major source of MGF after injury. Sustained MGF overexpression upregulated inflammatory markers and delayed the resolution of pro-inflammatory macrophages, likely by limiting macrophage apoptosis, without measurably improving regeneration outcomes. The result complicates the assumption that more MGF exposure is uniformly beneficial and is relevant to interpreting uncontrolled research use.
Safety & Tolerability
PEG-MGF has no human safety data of any kind: it has never been tested in humans, and the only human evidence is in vitro exposure of cultured muscle cells. Preclinical findings include depletion of the reserve progenitor cell pool in treated cultures of all ages and delayed macrophage resolution with sustained overexpression in mice. PEGylation itself has not been studied for this peptide in any published experiment.
Human data: No human clinical trials have been conducted or published. Human evidence is limited to in vitro studies on cultured human muscle progenitor cells. Human pharmacokinetics, safe exposure levels, and long-term effects are entirely uncharacterized.
Regulatory status: Not approved for human use anywhere; sold as a research chemical. Mechano growth factors are named on the WADA Prohibited List (section S2), so use by tested athletes constitutes an anti-doping violation.
- PubMed 21354439
The only human evidence is in vitro: the MGF E-peptide activated satellite cells from young but not elderly donors, and treated cultures of every age showed hypertrophy with depletion of the reserve cell population, indicating possible exhaustion of the progenitor pool under sustained exposure.
In-vitro - PubMed 30140235
In a mouse muscle injury model, sustained MGF overexpression upregulated inflammatory markers and delayed resolution of pro-inflammatory macrophages without improving regeneration outcomes, indicating chronic elevation may perturb normal repair.
Animal - PubMed 21354439
As a member of the IGF-1 family of growth factors, long-term mitogenic exposure carries a theoretical tumor-promotion concern; the argument that the E-peptide acts without the oncogenic signaling of full IGF-1 has never been tested in long-term animal or human studies.
Theoretical
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. PEG-MGF is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.
No human dosing exists. In the published literature, human muscle progenitor cell cultures were exposed to nanogram-per-milliliter concentrations of the synthetic MGF E-peptide, and rodent studies administered the unPEGylated peptide by local or systemic injection. PEGylation is intended to extend plasma persistence, but no formal pharmacokinetic study of PEG-MGF has been published in any species, and dosing schedules circulating in research communities have no validated basis.
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation
Yang SY, Goldspink G
FEBS Letters (2002)
This foundational study from University College London compared the biological activity of the MGF (IGF-1Ec) E domain against mature IGF-1 in myoblast cultures. The MGF E domain increased myoblast proliferation while inhibiting terminal differentiation, whereas mature IGF-1 promoted differentiation, establishing that the two products of the same gene play distinct and complementary roles in muscle adaptation. Blocking the IGF-1 receptor with a specific antibody abolished mature IGF-1 effects but not MGF E domain effects, the first evidence that the E-peptide acts through a separate receptor. The authors proposed that local MGF production after mechanical stress provides a tissue-specific repair signal, and noted that MGF production is markedly reduced in elderly and dystrophic muscle.
IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro
Stavropoulou A, Halapas A, Sourla A, et al.
Molecular Medicine (2009)
This study tracked IGF-1 splice variant expression in rat myocardium for up to 8 weeks after myocardial infarction and characterized synthetic MGF E-peptide signaling in H9C2 cardiomyocytes. Both IGF-1Ea and MGF transcripts rose during the late post-infarction period, supporting a role for local IGF-1 isoforms in myocardial repair. In vitro, a neutralizing anti-IGF-1R antibody completely blocked IGF-1-driven proliferation but failed to block MGF E-peptide action, and the peptide activated ERK1/2 phosphorylation without activating Akt. The work extended the IGF-1R-independent mechanism of the E-peptide beyond skeletal muscle into cardiac tissue.
A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success
Mills P, Dominique JC, Lafrenière JF, et al.
American Journal of Transplantation (2007)
This study tested whether a synthetic 24-amino acid peptide corresponding to the C-terminal MGF E domain (MGF-Ct24E) could improve human muscle precursor cell transplantation, a therapy under investigation for Duchenne muscular dystrophy. Intramuscular or systemic delivery of the peptide significantly promoted engraftment of human myogenic precursor cells in mice. In vitro experiments showed the peptide enhanced precursor cell proliferation through a mechanism independent of IGF-1 receptor binding and delayed their differentiation without affecting survival. The combined effects on proliferation and differentiation were proposed as the basis for the improved transplantation outcome.
Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages
Kandalla PK, Goldspink G, Butler-Browne G, et al.
Mechanisms of Ageing and Development (2011)
The most-cited direct study of the synthetic MGF-24aa-E peptide on human cells examined primary muscle cultures from donors of different ages. The peptide significantly increased the proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult donors, but not from old adult muscle, and it increased the fusion potential of activated progenitor cells. Hypertrophy accompanied by a significant decrease in the reserve cell population was observed in treated cultures across all age groups. The authors concluded the MGF E-peptide alone can enhance satellite cell activation, proliferation, and fusion for muscle repair and proposed it as a strategy against age-related sarcopenia that could avoid the oncogenic signaling associated with full-length IGF-1.
Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury
Sun KT, Cheung KK, Au SWN, et al.
Frontiers in Physiology (2018)
This in vivo study examined MGF function in cardiotoxin-injured mouse skeletal muscle. MGF expression rose sharply 1 to 2 days after injury and correlated with inflammatory cytokine expression; infiltrating macrophages, rather than neutrophils, were identified as the predominant source. Sustained MGF overexpression upregulated inflammatory markers and delayed resolution of the pro-inflammatory macrophage population, apparently by limiting macrophage apoptosis, and did not obviously improve muscle regeneration outcomes. The findings indicate that MGF participates in coordinating the inflammatory phase of muscle repair and caution that chronically elevated MGF exposure may perturb, rather than accelerate, the resolution of injury inflammation.
In vitro investigation of growth factors including MGF and IGF-1 in neural stem cell activation, proliferation, and migration
Tunç BS, Toprak F, Toprak SF, et al.
Brain Research (2021)
This comparative in vitro study screened MGF alongside FGF-2, IGF-1, EPO, EGF, NGF, and BDNF, alone and in combination, on rat hippocampal neural stem cells. MGF increased neurosphere size, indicating activity on neural progenitor cells, and drove cells out of quiescence into the mitotic phase. In contrast to FGF-2-containing combinations, MGF-containing combinations failed to protect the stem cells against apoptosis. The results show MGF bioactivity extends beyond muscle lineages while underscoring that its effects are context-dependent and not uniformly protective.
Frequently Asked Questions
What is the difference between MGF and PEG-MGF?
MGF (mechano growth factor, IGF-1Ec) is a natural splice variant of the IGF-1 gene whose unique E domain is expressed in muscle after mechanical stress. The synthetic research peptide is the 24-amino acid C-terminal fragment of that E domain. Like most short peptides it degrades within minutes in biological fluids, so vendors attach polyethylene glycol (PEG) to slow clearance - that conjugate is PEG-MGF. No published study has measured the pharmacokinetics of the PEGylated form, so the extended half-life is inferred from PEGylation chemistry rather than measured data.
Does PEG-MGF work through the IGF-1 receptor?
Published evidence says no. In three separate studies (Yang 2002, Mills 2007, Stavropoulou 2009), neutralizing antibodies against the IGF-1 receptor completely blocked mature IGF-1 but did not block the MGF E-peptide's effects on proliferation. In rat cardiomyocytes the peptide activated ERK1/2 without activating Akt, a signature distinct from canonical IGF-1R signaling. The actual receptor for the E-peptide has not been identified.
Has PEG-MGF been tested in humans?
No human clinical trial of MGF or PEG-MGF has been published as of 2026. The human evidence is limited to in vitro experiments on cultured human muscle cells, most notably the Kandalla 2011 study showing age-dependent activation of satellite cells. Safety, effective dosing, and pharmacokinetics in humans are entirely uncharacterized.
Is PEG-MGF banned in sport?
Yes. The World Anti-Doping Agency Prohibited List bans mechano growth factors by name under section S2 (peptide hormones, growth factors, related substances, and mimetics), alongside IGF-1. The prohibition applies at all times, in and out of competition, and covers MGF in any form including PEGylated conjugates.
Does age affect how muscle cells respond to MGF?
In the Kandalla 2011 human cell study, the MGF E-peptide extended the proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult donors, but cells from a 73-year-old donor did not respond this way. Across all ages, treated cultures showed hypertrophy with depletion of the reserve cell population. This suggests both that aging muscle responds differently and that sustained activation could consume the progenitor pool it expands.
Related Peptides
View allIGF-1 LR3
IGF-1 LR3 is a modified form of insulin-like growth factor-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension, designed to have reduced binding to IGF-binding proteins, which increases its free, biologically active fraction and potency.
Follistatin 344
Follistatin 344 is a naturally occurring glycoprotein that functions as a potent inhibitor of myostatin, activin, and other members of the TGF-beta superfamily. It has been extensively studied for its role in promoting skeletal muscle growth and as a gene therapy candidate for muscular dystrophy.
BPC-157
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied for its potential regenerative and protective properties in various tissue types.
TB-500
TB-500 is the N-terminally acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ, CAS 885340-08-9), identified analytically in TB-500 product by HPLC/high-resolution MS (PMID 22962027). It is studied for tissue repair, cell migration, and blood vessel formation. Product content is not reliable: a 2023 analysis of TB500/TB1000 sold online found contents inconsistent with the label, including full-length 43-residue thymosin beta-4 in place of the heptapeptide (PMID 36482504).
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.